Metformin use associated with decreased risk of colorectal cancer
the ONA take:
According to a new study published in the journal Cancer, researchers from the University of Chicago in Chicago, Illinois, have found that metformin use is associated with a decreased risk of developing colorectal cancer.
Metformin is typically the first-line oral treatment for patients with type 2 diabetes mellitus. For the study, researchers sought to examine the effects of metformin on colorectal cancer incidence in a U.S. population.
Using MarketScan databases, researchers identified patients with diabetes and colorectal cancer with each case being matched with up to two controls. The mean age of participants was 57 years for cases and 55 years for controls.
Results showed that metformin use was associated with a 15% risk reduction for the development of colorectal cancer, which was reduced to 12% after adjusting for health care use.
Researchers also found that there was no significant association between metformin dose, duration of treatment, or total exposure and risk of colorectal cancer.
Metformin use is associated with a decreased risk of developing colorectal cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|